{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:14:44Z","timestamp":1786986884513,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.clml.2021.06.010","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T06:50:27Z","timestamp":1624431027000},"page":"e820-e831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves"],"prefix":"10.1016","volume":"21","author":[{"given":"Neda","family":"Alrawashdh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel O","family":"Persky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joann","family":"Sweasy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Erstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.06.010_bib0001","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1016\/S0140-6736(18)30422-7","article-title":"Chronic lymphocytic leukaemia","volume":"391","author":"Hallek","year":"2018","journal-title":"The Lancet"},{"key":"10.1016\/j.clml.2021.06.010_bib0002","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1080\/17474086.2017.1398642","article-title":"Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia","volume":"10","author":"Innocenti","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"Suppl 4","key":"10.1016\/j.clml.2021.06.010_bib0003","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imj.13493","article-title":"Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil","volume":"47","author":"Tam","year":"2017","journal-title":"Intern Med J"},{"key":"10.1016\/j.clml.2021.06.010_bib0004","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ctrv.2014.11.004","article-title":"A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia","volume":"41","author":"Ladyzynski","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.clml.2021.06.010_bib0005","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3324\/haematol.2015.124693","article-title":"Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG)","volume":"100","author":"Cramer","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.06.010_bib0006","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2016.113","article-title":"Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL","volume":"30","author":"Maurer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2021.06.010_bib0007","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3324\/haematol.2018.200204","article-title":"First-line therapy in chronic lymphocytic leukemia: a Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013","volume":"104","author":"Sylvan","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.06.010_bib0008","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/asheducation-2016.1.137","article-title":"Novel agents in chronic lymphocytic leukemia","volume":"2016","author":"Lamanna","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2021.06.010_bib0009","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1056\/NEJMra1908213","article-title":"Treatment of chronic lymphocytic leukemia","volume":"383","author":"Burger","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clml.2021.06.010_bib0010","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41408-018-0131-2","article-title":"Chronic lymphocytic leukemia treatment algorithm 2018","volume":"8","author":"Parikh","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2021.06.010_bib0011","doi-asserted-by":"crossref","first-page":"djv396","DOI":"10.1093\/jnci\/djv396","article-title":"Targeted therapies improve outlook for chronic lymphocytic leukemia","volume":"107","author":"Brower","year":"2015","journal-title":"JNCI: Journal of the National Cancer Institute"},{"key":"10.1016\/j.clml.2021.06.010_bib0012","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clml.2021.06.010_bib0013","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.06.010_bib0014","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.clml.2021.06.010_bib0015","first-page":"185","article-title":"Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Wierda","year":"2020","journal-title":"Journal of the National Comprehensive Cancer Network: JNCCN"},{"key":"10.1016\/j.clml.2021.06.010_bib0016","series-title":"Presented at ASH Annual Meeting and Exposition","article-title":"Response Comes of Age in Chronic Lymphocytic Leukemia","author":"Woyach","year":"2019"},{"key":"10.1016\/j.clml.2021.06.010_bib0017","series-title":"Presented at ASH Annual Meeting and Exposition","article-title":"Debate Between Experts Ranges From Early-Stage Treatment Options to Current Role of Chemotherapy","author":"O'Brien","year":"2019"},{"key":"10.1016\/j.clml.2021.06.010_bib0018","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2288-11-61","article-title":"Network meta-analysis of survival data with fractional polynomials","volume":"11","author":"Jansen","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clml.2021.06.010_bib0019","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/jrsm.25","article-title":"Network meta-analysis of parametric survival curves","volume":"1","author":"Ouwens","year":"2010","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.clml.2021.06.010_bib0020","unstructured":"Mark Mitchell, Baurzhan Muftakhidinov, Tobias Winchen, Trande A. \"Engauge Digitizer Software\". Available at: http:\/\/markummitchell.github.io\/engauge-digitizer. Accessed August 21, 2020"},{"key":"10.1016\/j.clml.2021.06.010_bib0021","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/sim.1203","article-title":"Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects","volume":"21","author":"Royston","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.clml.2021.06.010_bib0022","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clml.2021.06.010_bib0023","unstructured":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) website. PRISMA statement. Available at: http:\/\/www.prisma-statement.org\/PRISMAStatement\/PRISMAStatement.aspx. Accessed June 18, 2020"},{"key":"10.1016\/j.clml.2021.06.010_bib0024","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the prisma statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.clml.2021.06.010_bib0025","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions","volume":"370","author":"Goede","year":"2014","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.clml.2021.06.010_bib0026","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.06.010_bib0027","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.clml.2021.06.010_bib0028","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3324\/haematol.2017.170480","article-title":"Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study","volume":"103","author":"Michallet","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2021.06.010_bib0029","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"The New England journal of medicine"},{"key":"10.1016\/j.clml.2021.06.010_bib0030","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2016.68.2856","article-title":"Economic burden of chronic lymphocytic leukemia in the era of oral targeted therapies in the United States","volume":"35","author":"Chen","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clml.2021.06.010_bib0031","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.clml.2019.08.004","article-title":"Comparison of time to next treatment, health care resource utilization, and costs in patients with chronic lymphocytic leukemia initiated on front-line ibrutinib or chemoimmunotherapy","volume":"19","author":"Emond","year":"2019","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2021.06.010_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-134119","article-title":"A clinical practice comparison of overall survival, time-to-next-treatment, and time-to-treatment-discontinuation among CLL\/SLL patients receiving first-line ibrutinib with and without a Del(17p) Mutation","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.06.010_bib0033","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2217\/cer-2017-0086","article-title":"Front-line treatment of patients with chronic lymphocytic leukemia: a systematic review and network meta-analysis","volume":"7","author":"Xu","year":"2018","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.clml.2021.06.010_bib0034","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1016\/j.clinthera.2020.08.017","article-title":"Comparative Efficacy of Acalabrutinib in Frontline Treatment of Chronic Lymphocytic Leukemia: a systematic review and network meta-analysis","volume":"42","author":"Davids","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.clml.2021.06.010_bib0035","doi-asserted-by":"crossref","first-page":"5616","DOI":"10.1200\/JCO.2007.12.9098","article-title":"Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia","volume":"25","author":"Hillmen","year":"2007","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265021002391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:38:04Z","timestamp":1761871084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265021002391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S2152265021002391"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.06.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}